This inventor holds 2 USPTO granted patents and 2 published patent applications and 2 EPO patents. Top assignees: Boehringer Ingelheim Rcv Gmbh & Co. Kg, Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E. V. , Sandoz Ag. Active years: 2012-2017.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 19 
1 out of 1,335 
1 out of 149 
Years Active: 2012-2017
Title: Rainer Schneider: Innovator in Recombinant Protein Technology
Introduction: Rainer Schneider, an accomplished inventor based in Wörgl, Austria, has made significant contributions to the field of biopharmaceuticals, particularly focusing on recombinant protein technologies. With a portfolio of two patents, Schneider stands out in the realm of scientific innovation, specifically targeting disease treatment strategies involving microtubule-associated protein phosphatase 2A (PP2Ac).
Latest Patents: Schneider's latest patents focus on methods for producing a recombinant protein of interest. The first invention involves a method for preventing or treating diseases associated with non-physiological levels of intracellular PP2Ac. This innovative method comprises administering a pharmaceutically effective amount of proteins MID1 or MID2 to affected subjects. Furthermore, it extends to treatment strategies aimed at conditions resulting from both increased and decreased levels of PP2Ac, demonstrating the versatility and applicability of his research.
Career Highlights: Rainer Schneider has garnered invaluable experience working with renowned companies such as Sandoz AG and Boehringer Ingelheim RCV GmbH & Co. KG. His work in these esteemed organizations underscores his commitment to advancing healthcare solutions through scientific research and development. Schneider's career showcases a progressive engagement in biotechnology, enhancing his expertise in recombinant protein production methods.
Collaborations: Throughout his career, Schneider has collaborated with notable professionals, including Maria Reitmeir and Bernhard Auer. These partnerships not only highlight his ability to work effectively within teams but also emphasize the interdisciplinary nature of modern scientific endeavors, fostering innovation that transcends individual contributions.
Conclusion: Rainer Schneider's innovative work in the field of recombinant proteins positions him as a key figure in biopharmaceutical research. His patents reflect a deep understanding of complex biological processes and a commitment to developing effective treatments for diseases linked to PP2Ac levels. As he continues to contribute to advancements in biotechnology, Schneider exemplifies the spirit of innovation that drives progress in the field of medicine.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile